Core Viewpoint - The stock of Fuhong Hanlin (02696) has seen an increase of over 5% during trading, currently up 4.39% at HKD 66.65, with a trading volume of HKD 23.9053 million [1] Group 1: Clinical Data Announcement - Fuhong Hanlin has announced clinical data for its PD-L1 ADC drug HLX43, which is aimed at treating recurrent/metastatic esophageal squamous cell carcinoma (ESCC) [1] - HLX43 is a novel ADC drug targeting PD-L1, combining immune checkpoint inhibition with cytotoxic effects, showing promising efficacy and good tolerability in patients who are unresponsive to immunotherapy [1] - The Phase II study aims to evaluate the efficacy and safety of HLX43 in patients with treated recurrent/metastatic esophageal squamous cell carcinoma [1]
港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据